About PILA PHARMA
PILA PHARMA is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden.
The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
XEN-D0501 is a synthetic small molecule that was in-licensed in 2016.
Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups.
PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes.
Further, PP-CT02, demonstrated that XEN-D0501 (administered as 4 mg BID for 28 days) – with statistical significance versus placebo – enhance the endogenous insulin response to oral glucose.
FÅ PRESSMEDDELANDEN / GET PRESS RELEASES
Läs hela artikeln (in Swedish) här
PILA PHARMA publishes interim report for July 1 – September 30, 2021
Our COO, Lars Bukhave Rasmussen (and possibly som other PILAs), will be attending “The Future of Swedish & Danish Life Science” meeting in Lund, Sweden September 2nd 2021.
Read more (in English) here
Read more (in Danish) here
PILA PHARMA AB is off
Our listing on Nasdaq was one ‘once in a life-time’ event and our CEO want to thank everybody involved in making it happen.
Very pleased that Nasdaq last week gave PILA PHARMA AB the final approval for the list. We look forward to ‘first trading day’ on Thursday 15 July 2021.
For your information, our ‘ticker’ ‘PILA’
Read more (in English) here
On 16 June, Børsen published this well-written article on PILA PHARMA AB by Kevin Grønnemann commented by Senior Equity Analyst Søren Løntoft Hansen at Sydbank. I was pleased to see, that Søren, believe ‘it can be done’! With Sørens permission, I’m pleased to share an English summary of his statements: “Even though it will not be an easy task, I think that a compound that effectively lowers blood glucose, has a good safety profile and perhaps addresses some of the co-morbidities of diabetes as cardio-vascular disease, can be made. If, on top, the compound can be marketed at lower cost, then I actually believe it has potential!”. (in Danish) here
(16 june 2021)
We are so incredibly honoured to share that the American Diabetes Association(ADA) is featuring PILA PHARMA AB in the Thought Leadership Film Series, a part of ADA’s 81st Scientific Sessions program in June 2021, starting today.
In the invitation letter, it was written: We are interested in profiling Pila’s pioneering research and development in the science surrounding TPRV1 inhibition, and how regulation of this mechanism has tremendous potential to be exploited for the treatment of diabetes. The pandemic has triggered a diabetes crisis of another sort, having multiplied the complications associated with the disease and has left diabetics more vulnerable than ever before. The pandemic has further underscored the dire need for innovative approaches that go beyond the conventional realms of the diabetes field, and therefore facilitating this is the primary focus for ADA TV this year. There is substantial pre-clinical evidence indicating a role for TPRV1 in metabolic diseases, however this novel avenue has never really been pursued despite its potential. Given that Pila Pharma is one of the few organisations that is working in this innovative space, we believe that it has the potential to make an incredibly valuable addition to this year’s series, as many in the diabetes community could learn and benefit greatly from the story behind your work.”
What at great honour – it fuels us with energy and strength to overcome all challenges ahead in order to eventually provide our new type of diabetes treatment to people with diabetes in need there off!
Watch the video in English here
(24 june 2021)
Thank you to Millionærklubben and Pernille Enggaard for paying attention to us and for yesterdays radio-interview of our CEO. You can listen to it here (in Danish), time 19:09 to 37:5 here